Semiconductor technology empower biomedical, Xinsu Technology has completed tens of millions of yuan angel round financing

The investment community on July 20th, Xinsu Technology was established in 2021 and is committed to using semiconductor technology to empower biomedical. At present, tens of millions of yuan of angel round financing has been completed. This round of financing is led by Fengrui Capital, and Jiacheng Capital follows.

Semiconductor technology has changed all aspects of human medicine and biotechnology in the 50 years of “stuck neck” in my country. Since Midunli developed the first portable pacemaker based on transistor-based pipes, various planting equipment followed the development of semiconductor technology. The volume is getting smaller and smaller, the functions are getting stronger, and the trauma has become less and less. Now, semiconductor technology has continued to develop by Moore’s Law. The key scale of the top-down transistors has been reduced to several nanometers, which is similar to that of biomolecules such as DNA and protein. In the future, the cross between semiconductor technology and biotechnology will give birth to a trillion-dollar market.

The founding teams formed by the company’s vision are Dr. MIT and have accumulated more than ten years of research and development in semiconductor, micro-current control, and biotechnology. Co-founder Zhao Xin graduated from the School of Physics of Peking University in the first place undergraduate. He then studied Ph.D. at MIT, engaged in semiconductor technology and device research, and was selected for a national talent program. For the first time internationally, Zhao Xin has designed and prepared the world’s smallest and highest-directed vertical structure field effect tube (MOSFET). It was selected as the most ideal field effect tube of the industry in the next two decades by the 2017 international component and system blueprint. It is one of the most powerful competitors in the next generation of integrated circuit components. This device technology has published more than 40 papers (Google Scholar quoted more than 700 times), and his work was followed up by many top scientific research teams in the world (Eli Yablonovitch, Academician of the Fourth Institute of the United States) and high evaluation (Academician Huang Ru and Academician Hao Yue of the Chinese Academy of Sciences Wait), its research results of semiconductor devices are adopted by international leading semiconductor companies including TSMC, IBM, IMEC, Sematech, LAM Research and Oxford Instruments, which verify the entire process of transforming innovative technology into products and gradually landing in the industry. Co-founder Wu Dan graduated from the MIT Machinery Department. He has more than 10 years of scientific research and industrial experience in ultrasonic images, biochemical, cell control, and microfluidic control technology. The POC immunogen detection platform, is applied by the Norhua Biomedical Research Center to monitor CAR-THERAPY patients’ cytokine release syndrome. In 2021, Zhao Xin and Wu Dan returned from the United States to China to jointly establish Xinsu Technology.

The small and highly integrated characteristics of silicon chips and microfluidic control technology can provide ultra-high and high-sensitivity. Xinsu Technology will use its biological chip platform to first cut into the synthesis and synthesis of single molecules (DNA and protein). Test. DNA synthesis is a necessary means in the process of exploring the mystery of life. It plays a pivotal role in the fields of synthetic biology, DNA storage, and antibody drug screening. DNA synthesis radiation is over 100 billion US dollars, but the existing DNA synthesis technology is far from meeting the requirements of low cost, high throughput, and high accuracy. On the other hand, the protein molecules expressed by DNA as the carrier of life can most directly reflect the physiological and healthy state of the human body. The immune testing is hot, and the protein group is in the ascendant. Clinical diagnosis and scientific research put forward higher requirements for the sensitivity of immune testing, such as Elisa 1000 times higher. Single molecular detection of protein is an important and huge application direction. It can be seen that whether it is the DNA synthetic market or the immunoblastic detection market, it still has huge expansion potential. Xinsu Technology will use silicon chips and micro-current control to develop a new generation of DNA synthesis technology. Market blue ocean.

Xinsu Technology is committed to designing and manufacturing silicon and microfluidic chips to develop a new generation of DNA synthesis technology, which will greatly reduce the cost of long-chain DNA synthesis to meet the needs of the rapid development of synthetic biology and DNA storage. At the same time, with the use of the same technology platform, Xinsu Technology is also developing a digital immune detection system with a higher sensitivity of 2 to 3 or more than the traditional testing method to meet the requirements of the detection of low-rich protein logo in clinical and life science research.

Li Feng, the founding partner of Fengrui Capital, said: “Congratulations on the establishment of Xinsu Technology, which is another project from Boston, USA, and another front -edge cross -tech project for our layout. This area is also the two areas of innovation and concentration. In the cross nodes of these two fields, young scientists at MIT explore the application of synthetic biology and single molecular detection. We are very optimistic about the team’s great achievements. ”

Ma Rui, executive director of Fengrui Capital, said: “Xinsu Technology has gathered in the cross-cutting the field of biomedical and chips. As a new intelligent infrastructure, chip + micro-current control can often provide a really high -throughput for biological scenarios, Ultra -high -sensitive detection capabilities, and highly integrated light hardware. The founding team of Xinju Technology is Dr. MIT. It has many years of industrial experience and profound technology in the design and manufacturing fields of biological chips, sensors, micro-current control systems, MEMS, etc. Accumulation. Very optimistic about the company’s use of new biological chips and semiconductor technology to explore DNA high-throughput synthesis in the field of synthetic biology, as well as the implementation of single molecular detection in the field of digital immunization. ”

http://oaicon.com/index.php/2023/02/27/semiconductor-technology-empower-biomedical-xinsu-technology-has-completed-tens-of-millions-of-yuan-angel-round-financing/

Li Li, the founding partner of Jiacheng Capital, said: Xinsu Technology Team represents the style of China’s new generation of biotechnology entrepreneurs. They come from the world’s top scientific research institutions or colleges and have an international perspective’s independent innovation research and development capabilities. The development of biotechnology has a strong sense of mission. Jiacheng and Xinao Technology have been known for a long time. They participated in the research process and were deeply determined by the founder Zhao Xin to promote industrial innovation. Seeing the trend of cross-integration of chips and biotechnology, Jiacheng Capital will accompany Xin Su to accompany Xinsu Suzuki Technology explores the innovative future of biological chips in China. “